ProCE Banner Activity

Melanoma Decision Support Tool

Tool

Compare your choice of therapy for patients with stage III or IV melanoma with 5 expert recommendations using this Interactive Decision Support Tool.

Released: August 03, 2023

Share

Faculty

Hussein Tawbi

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Adil Daud

Adil Daud, MD

Clinical Professor of Medicine
Department of Medicine, Division of Hematology/Oncology
University of California
Professor of Medicine, Melanoma Oncology
UCSF
San Francisco, California

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Ahmad Tarhini

Ahmad Tarhini, MD, PhD

Professor
Department of Oncologic Services
University of South Florida Morsani College of Medicine
Senior Member
Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Program Director Disclosure

Program Director

Hussein Tawbi, MD, PhD

Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hussein Tawbi, MD, PhD: consultant/advisor/speaker: Bristol Myers Squibb, Boxer Capital, Eisai, Genentech, Ivoance, Jazz, Karyopharm, Medicenna, Merck, Novartis; researcher: Bristol Myers Squibb, Dragonfly Therapeutics, Eisai, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, RAPT Therapeutics.

Faculty Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD: consultant/advisor/speaker: Bristol-Myers Squibb, Immatics, Instil Bio, Iovance, Lyell Immunopharma, Novartis, Pfizer; researcher: Iovance.

Adil Daud, MD

Clinical Professor of Medicine
Department of Medicine, Division of Hematology/Oncology
University of California
Professor of Medicine, Melanoma Oncology
UCSF
San Francisco, California

Adil Daud, MBBS, has no relevant financial relationships to disclose.

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan Lipson, MD: consultant/advisor/speaker: Bristol-Myers Squibb, CareDx, Eisai, Genentech, Immunocore, InstillBio; researcher: Bristol-Myers Squibb, Merck, Sanofi/Regeneron.

Ahmad Tarhini, MD, PhD

Professor
Department of Oncologic Services
University of South Florida Morsani College of Medicine
Senior Member
Departments of Cutaneous Oncology & Immunology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Ahmad Tarhini, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Instil Bio, Merck; researcher: Clinigen, Genentech/Roche, Nektar, Regeneron, Sanofi/Genzyme.